HOME >> BIOLOGY >> NEWS
Anticancer drug reveals alternate means of inducing cell suicide

Derivatives of the COX-2 inhibitor celecoxib can trigger cancer cell suicide, or apoptosis, but not necessarily through the recognized means of blocking COX-2 enzyme activity, a new study concludes. By separating COX-2 activity from apoptosis, researchers have a starting point for designing new classes of anticancer drugs, write Xueqin Song, Ching-Shih Chen, Ph.D., Ohio State University, and their coworkers in the April 17 issue of the Journal of the National Cancer Institute.

Celecoxib, an anti-inflammation pill for arthritis, is being studied for its potential in preventing and treating certain cancers. In a large percentage of tumors, the COX-2 enzyme is elevated, say Ernest T. Hawk, M.D., M.P.H., of the National Cancer Institute, and his coworkers in an accompanying editorial. They point out that past studies have shown that decreasing levels of COX-2 can suppress the growth of tumors. However, it has been unclear whether celecoxibs anticancer effects depend on COX-2 inhibition alone.

To find out, Chen and his coworkers created prostate cancer cells lacking the COX-2 enzyme. In contrast to the effects of COX-2 inhibitors such as celecoxib, which induce cell death, cells that lacked COX-2 remained alive. Exposure of these cells lacking COX-2 to various COX-2 inhibitors did lead to cell death. Whats more, derivatives of celecoxib that did not block COX-2 activity also caused cell death.

The authors note that these events were associated not with levels of COX-2 but with decreased phosphorylation of Akt and ERK2 proteins. This mode of action differs from that of conventional anticancer drugs, they point out.

In the accompanying editorial, Hawk and his colleagues note that celecoxib is being tested for the treatment and prevention of colon cancer and that newer generations of COX-2 inhibitors could prove to be safer and more effective.

However, they point out that the current findings are based on concentrations of c
'"/>

Contact: Linda Wang
jncinews@oup-usa.org
301-841-1287
Journal of the National Cancer Institute
16-Apr-2002


Page: 1 2

Related biology news :

1. Anticancer drug zebularine specifically targets tumor cells
2. The Bodys Anticancer Weaponry Backfires In Old Age
3. Enzymes "Magic" May Hold Key to Anticancer and Antimicrobial Drugs
4. Hidden diversity: DNA barcoding reveals a common butterfly is actually 10 different species
5. Brown research reveals key insight into memory-making
6. Study reveals why eyes in some paintings seem to follow viewers
7. New dye directly reveals activated proteins in living cells
8. Study reveals first genetic step necessary for prostate cancer growth
9. Study of flu patients reveals virus outsmarting key drug
10. Study in Science reveals recreational fishing takes big bite of ocean catch
11. Plumbing trees plumbing reveals their engineering skill

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/8/2016)... , March 8, 2016   Valencell ... technology, today announced it has secured $11M in ... GII Tech, a new venture fund being launched ... additional participation from existing investors TDF Ventures and ... funds to continue its triple-digit growth and accelerate ...
(Date:3/3/2016)... MONTEREY, Calif. , March 3, 2016 /PRNewswire/ ... Partner, launched this week highlighting advancements in flexible, ... – a record setting attendance - have gathered ... in this fast-growing field of electronics. The Flex ... a focal point for companies, R&D organizations, and ...
(Date:3/2/2016)... March 2, 2016 ... addition of the  "Global Biometrics Market in ... ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , , Global biometrics ... at a CAGR of around 27%   ... has announced the addition of the  "Global ...
Breaking Biology News(10 mins):
(Date:5/4/2016)... N.J. , May 4, 2016  Bayer ... its oncology compound Stivarga ® (regorafenib) tablets ... carcinoma (HCC) has met its primary endpoint of ... study, called RESORCE, evaluated the efficacy and safety ... has progressed after treatment with sorafenib. The safety ...
(Date:5/4/2016)... New York, NY (PRWEB) , ... May 04, ... ... growth, has leveraged recent innovations in biotechnology to help treat hormonal and stress ... hair loss, Nutrafol® has captured the hearts of key opinion leaders in the ...
(Date:5/3/2016)... ... 03, 2016 , ... Leading CEOs from biotech, pharmaceutical, and ... June 1st at The Four Seasons Hotel Boston. , The Boston CEO Conference ... exclusive access to key decision makers who influence deal making and investment. Attendees ...
(Date:5/3/2016)... -- - And Other Rising Companies - ... Competitor Biologics  - Biosimilar Drug Producers - ... Who are the most important and promising ... sales potentials? Discover, in our updated survey, organisations, outlooks ... revenue forecasting. Visiongain,s new study ...
Breaking Biology Technology:
Cached News: